睿昂基因
(688217)
| 流通市值：13.83亿 | | | 总市值：13.83亿 |
| 流通股本：5585.59万 | | | 总股本：5585.59万 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 79,836,487.02 | 35,864,096.63 | 177,260,777.73 | 139,103,619.1 |
| 营业收入 | 79,836,487.02 | 35,864,096.63 | 177,260,777.73 | 139,103,619.1 |
| 二、营业总成本 | 84,388,710.24 | 40,535,955.17 | 196,970,472.1 | 153,715,390.64 |
| 营业成本 | 18,034,316.46 | 7,759,415.73 | 43,640,542.17 | 36,927,288.05 |
| 税金及附加 | 1,608,833.6 | 748,254.61 | 3,337,155.86 | 2,536,509.12 |
| 销售费用 | 22,123,486.91 | 13,433,236.32 | 47,701,902.01 | 36,259,341.83 |
| 管理费用 | 21,637,221.46 | 9,100,774.39 | 50,293,943.45 | 36,752,893.62 |
| 研发费用 | 19,387,603.35 | 9,132,538.47 | 52,995,190.92 | 42,449,127.26 |
| 财务费用 | 1,597,248.46 | 361,735.65 | -998,262.31 | -1,209,769.24 |
| 其中:利息费用 | 40,470.05 | - | 192,695.58 | - |
| 其中:利息收入 | 78,208.31 | - | 2,257,817.46 | - |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -273,211.26 | -32,348.57 | 1,245,915.61 | -47,298.98 |
| 加:投资收益 | 5,867,947.13 | 550,422.46 | 2,371,403.58 | 1,709,855.46 |
| 资产处置收益 | 109,388.28 | -285,453.79 | 128,618.81 | 47,904.94 |
| 资产减值损失(新) | -3,966,838.6 | -87,028.42 | -29,240,817.07 | -355,913.78 |
| 信用减值损失(新) | -8,290,317.96 | -4,061,150.58 | -13,880,799.21 | -7,222,974.28 |
| 其他收益 | 1,114,179.79 | 597,981.77 | 9,709,802.31 | 4,484,070.5 |
| 四、营业利润 | -9,991,075.84 | -7,989,435.67 | -49,375,570.34 | -15,996,127.68 |
| 加:营业外收入 | 0.95 | 0.94 | 138,913.73 | 8,582.22 |
| 减:营业外支出 | 368,074.68 | 35,298.56 | 1,492,593.1 | 525,314.13 |
| 五、利润总额 | -10,359,149.57 | -8,024,733.29 | -50,729,249.71 | -16,512,859.59 |
| 减:所得税费用 | 7,300,595.17 | -1,139,578.96 | 9,690,851.95 | -4,203,906.71 |
| 六、净利润 | -17,659,744.74 | -6,885,154.33 | -60,420,101.66 | -12,308,952.88 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -17,659,744.74 | -6,885,154.33 | -60,420,101.66 | -12,308,952.88 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -12,340,876.58 | -4,983,192.9 | -50,377,077.79 | -5,620,662.24 |
| 少数股东损益 | -5,318,868.16 | -1,901,961.43 | -10,043,023.87 | -6,688,290.64 |
| 扣除非经常损益后的净利润 | -18,514,751.02 | -5,449,643.49 | -62,257,424.04 | -12,197,962.85 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.22 | -0.09 | -0.91 | -0.1 |
| (二)稀释每股收益 | -0.22 | -0.09 | -0.91 | -0.1 |
| 八、其他综合收益 | - | - | -4,622,209.64 | - |
| 归属于母公司股东的其他综合收益 | - | - | -4,622,209.64 | - |
| 九、综合收益总额 | -17,659,744.74 | -6,885,154.33 | -65,042,311.3 | -12,308,952.88 |
| 归属于母公司股东的综合收益总额 | -12,340,876.58 | -4,983,192.9 | -54,999,287.43 | -5,620,662.24 |
| 归属于少数股东的综合收益总额 | -5,318,868.16 | -1,901,961.43 | -10,043,023.87 | -6,688,290.64 |
| 公告日期 | 2026-08-28 | 2026-04-28 | 2026-04-11 | 2025-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |